Prevention of acute lung allograft rejection in rat by CTLA4Ig

American Journal of Transplantation

Volumn 2, Issue 3, 2002, Pages 223-228

  Shiraishi, Takeshi ^a   Yasunami, Yohichi ^a   Takehara, Megumi ^b   Uede, Toshimitsu ^b   Kawahara, Katsunobu ^a   Shirakusa, Takayuki ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Costimulatory signal; CTLA4Ig; Lung; Rejection; Transplantation; Transplantation tolerance

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MALE; NONHUMAN; RAT; RAT STRAIN; SKIN GRAFT; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; RATS; RATS, INBRED BN; RATS, INBRED F344; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036523975     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.20306.x     Document Type: Article

References (45)

1. Mason DW, Morris PJ. Effecter mechanisms in allograft rejection. Annu Rev Immunol 1986; 4: 119-145.
2. Krensky AM, Weiss A, Crabtree G, Davis M, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322: 510-517.
3. Linsley PS, Brady W, Urnes M et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
4. Freeman GJ, Gribben JG, Boussiotis VA et al. Cloning of B7-2: a CTLA4 counter receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
5. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87: 5031-5035.
6. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
7. Walunas TL, Bakker CY, Bluestone JA. CTLA4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-2550.
8. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo required CTLA4 engagement. Immunity 1997; 6: 411-417.
9. Issazadeh S, Zhang M, Sayegh MH, Khoury SJ. Acquired thymic tolerance. role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model, J Immunol 1999; 162: 761-765.
10. Turka L, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102-11105.
11. Judge TA, Wu Z, Zheng XG et al. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162: 1947-1951.
12. Lenschow DJ, Zeng R, Thistlethwaite R et al. Long term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789-792.
13. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-1227.
14. Khoury SJ, Akalin E, Chandracter A et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents activity induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155: 4521-4524.
15. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
16. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/ CTLA4: B7/BB1 interaction with CTLA4Ig reduces lethal murine graft-versus-host disease across major histocompatibility complex barrier in mice. Blood 1994; 83: 3815-3825.
17. Krinzman SJ, De Sanctis GT, Cernandas M et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996; 98: 2693-2699.
18. Bluestone JA. Is CTLA4 a master switch for peripheral T cell tolerance? J Immunol 1997; 158: 1989-1993.
19. Lin H, Bolling S, Linsley P et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusions. J Exp Med 1993; 178: 1801-1806.
20. Pearson TC, Alexander DZ, Winn KJ et al. Transplantation tolerance induced by CTLA4Ig. Transplantation 1994; 57: 1701-1706.
21. Tarumi K, Murakami M, Yagihashi A et al. CTLA4Ig treatment induces long term acceptance of rat small bowel allografts. Transplantation 1999; 67: 520-525.
22. Yamada A, Konishi K, Cruz GLE et al. Blocking the CD28-B7 T cell costimulatory pathway abrogates the development of obliterative bronchiolitis in a murine heterotopic airway model. Transplantation 2000; 69: 743-749.
23. Bolling SF, Lin H, Wei RQ, Turka LA. Preventing allograft rejection with CTLA4Ig: effect of donor-specific transfusion route or timing. J Heart Lung Transplant 1996; 15: 928-935.
24. Jordan SC, Matsumura Y, Zuo XJ, Marchevsky A, Linsley P, Matloff J. Donor specific transfusions enhance the immunosuppressive effects of single dose cyclosporine A and CTLA4Ig but do not result in long term graft acceptance in a histocompatible model of rat lung allograft rejection. Transplant Immunol 1995; 4: 33-37.
25. Matsumura Y, Zuo XJ, Prehn J et al. Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic inflammation or transcription of key cytokines. Transplantation 1995; 59: 551-558.
26. Ugurlu M, Griffin MD, O'Brien T, Tazelaar HD, Miller VM, McGregor GA. The effect of CTLA4Ig on acute lung allograft rejection: a comparison of intrabronchial gene therapy with systemic administration of protein. Transplantation 2001; 71: 1867-1871.
27. Nakagawa I, Murakami M, Ijima K et al. Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG. Hum Gene Ther 1998; 9: 1739-1745.
28. Shiraishi T, Kawahara K, Shirakusa T et al. Inhaled nitric oxide does not increase rat lung rejection. J Heart Lung Transplant 1998; 17: 573-577.
29. Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1-15.
30. Billingham RE, Medawer PB. Technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
31. Bluestone JA. New perspectives of CD28-B7 mediated T cell costimulation. Immunity 1995; 2: 555-559.
32. Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigen challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869-1874.
33. Tran HM, Nickerson PW, Restifo AC et al. Distinct mechanism for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997; 159: 2232-2239.
34. Kearney ER, Walnus TL, Karr RW et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4. J Immunol 1995; 155: 1032-1036.
35. Judge TA, Tang A, Spain LM et al. The in vivo mechanisms of action of CTLA4Ig. J Immunol 1996; 156: 2294-2299.
36. Larsen CP, Elwood ET, Alexander DZ et al. Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
37. Nishikawa K, Linsley P, Collins A, Stamenkovic I, McClusky R, Andres G. Effect of CTLA4I chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 1994; 24: 1249-1254.
38. Austyn JM, Kupiec-Weglinski JW, Hankings DF, Morris PJ. Migration patterns of dendritic cells in the mouse. J Exp Med 1988; 167: 646-651.
39. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts in host spleens. J Exp Med 1990; 171: 307-314.
40. Lakkis FG, Konieczny BG, Saleem S et al. Blocking the CD28 B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158: 2443-2448.
41. Baligna P, Chavin KD, Qin L et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58: 1082-1990.
42. Woodward JE, Qin L, Chavin KD et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation 1996; 62: 1011-1018.
43. Yang Z, Rostami S, Koeberkein B, Barker CF, Naji A. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig. Transplantation 1999; 67: 1517-1523.
44. Bolling SF, Lin H, Turka LA. The time course of CTLA4Ig effect on cardiac allograft rejection. J Surg Res 1996; 63: 320-323.
45. Yin D, Fathman CG. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. J Immunol 1995; 155: 1655-1659.